ArticlePathogens (Basel, Switzerland)2020
In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus.
Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- The inactivation of the Niemann Pick C1 cholesterol transporter restricts SARS-CoV-2 entry into host cells by decreasing ACE2 abundance at the plasma membrane.Cell & bioscience · 2024Article
- Review
- Rottlerin-Liposome Inhibits the Endocytosis of Feline Coronavirus Infection.Veterinary sciences · 2023Article
- Lipid compartments and lipid metabolism as therapeutic targets against coronavirus.Frontiers in immunology · 2023Review
- Polyamine-Linked Cholesterol Incorporation in Rift Valley Fever Virus Particles Promotes Infectivity.ACS infectious diseases · 2022Article
- NPC1-regulated dynamic of clathrin-coated pits is essential for viral entry.Science China. Life sciences · 2022Article
- Feline Coronavirus Antivirals: A Review.Pathogens (Basel, Switzerland) · 2021Review
- A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry.Nature communications · 2021Article
- Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.The veterinary quarterly · 2020Review
- Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.Genomics & informatics · 2020Article
- Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis.The Journal of veterinary medical science · 2020Article
- Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.Journal of lipid research · 2020Review
- The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Relation of Dietary Factors with Infection and Mortality Rates of COVID-19 across the World.The journal of nutrition, health & aging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.